Plain-English translation of NCT06925542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing , a new type of cell therapy for people with severe autoimmune diseases like lupus, systemic sclerosis, or inflammatory myopathy that haven't improved with standard medicines. The medication is made from immune cells taken from healthy volunteers and genetically modified using CRISPR technology—a precise gene-editing tool—to help calm down your overactive immune system. This is an early-stage trial designed to see if this treatment is safe and whether it helps reduce disease symptoms.
Many people with severe autoimmune diseases don't respond well enough to the medications currently available, and their conditions continue to cause serious organ damage. This trial exists to test whether this new genetically edited cell therapy could offer a new option for patients who have exhausted standard treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive chemotherapy to prepare your body to receive the new cells. You will then receive the genetically modified cells through an intravenous infusion (IV, through a vein). You will need to return to the clinic regularly for blood tests, imaging studies, and checkups to monitor how the treatment is working and watch for any side effects. The study will carefully track your symptoms and disease activity over time to see if this new therapy helps you.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States